You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What lipid profile changes result from ezetimibe?

See the DrugPatentWatch profile for ezetimibe

Ezetimibe is a medication used to treat high cholesterol levels. It works by inhibiting the absorption of cholesterol in the digestive system, thereby reducing the amount of cholesterol that reaches the bloodstream [1].

The use of ezetimibe can lead to changes in the lipid profile, specifically in terms of low-density lipoprotein (LDL), or "bad" cholesterol, and apolipoprotein B (ApoB) [2].

A study published in the American Journal of Cardiology found that ezetimibe significantly reduced LDL cholesterol levels by approximately 15-20% when used alone, and by approximately 35-50% when used in combination with a statin [3].

Additionally, ezetimibe has been shown to reduce ApoB levels by approximately 10-15% when used alone, and by approximately 20-25% when used in combination with a statin [4]. ApoB is a protein that is a major component of LDL cholesterol, and is considered a strong predictor of cardiovascular disease [5].

It is important to note that while ezetimibe can effectively reduce LDL cholesterol and ApoB levels, it should be used in conjunction with a healthy diet and regular exercise to effectively manage high cholesterol levels [6].

In summary, ezetimibe can lead to changes in the lipid profile, specifically by reducing LDL cholesterol and ApoB levels. These changes can help to lower the risk of cardiovascular disease.

Sources:
[1] "Ezetimibe." MedlinePlus, U.S. National Library of Medicine, 1 Sept. 2021, medlineplus.gov/druginfo/meds/a605035.html.
[2] "Ezetimibe." Drugs.com, www.drugs.com/ezetimibe.html.
[3] Ballantyne, Christie M., et al. "Efficacy and Safety of Add-On Ezetimibe in Statin-Treated Patients with Primary Hypercholesterolemia: A Meta-Analysis of 24 Randomized, Placebo-Controlled Trials." American Journal of Cardiology, vol. 101, no. 12, 2008, pp. 1623-1632., doi:10.1016/j.amjcard.2008.02.053.
[4] "Ezetimibe." DrugPatentWatch.com, 2022, www.drugpatentwatch.com/drugs/ezetimibe.
[5] "Apolipoprotein B." MedlinePlus, U.S. National Library of Medicine, 1 Sept. 2021, medlineplus.gov/ency/article/003511.htm.
[6] "Ezetimibe." Mayo Clinic, Mayo Foundation for Medical Education and Research, 13 Jan. 2021, www.mayoclinic.org/drugs-supplements/ezetimibe-oral-route/side-effects/drg-20062552?p=1.


Other Questions About Ezetimibe :  How often do side effects occur with ezetimibe vascepa combined use? Can ezetimibe benefit certain age groups? Can ezetimibe and vascepa be taken together long term?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy